Research is our foundation
Lundbeck is devoted to the treatment of psychiatric and neurological disorders. We dedicate our entire R&D efforts to develop innovative drugs for treatment of a number of psychiatric and neurological disorders. Our R&D projects focus on:
- Alzheimer’s disease
- Parkinson’s disease
Read more about our disease areas.
Underlying disease biology
Lundbeck’s R&D strategy is aimed at enabling the discovery and development of new pharmaceuticals targeting the underlying mechanisms of brain diseases. This approach allows us to treat the symptoms more effectively and potentially also to alter the course of the diseases. The strategy requires comprehensive research into the brain and the biology and mechanisms of brain diseases, as well as improved understanding of research targets and clinical outcomes.
Essential to the R&D strategy is for Lundbeck to maintain strong internal R&D capabilities in order to establish optimal networks and partnerships. We will continue to build external alliances to supplement our internal capabilities, taking advantage of the increased opportunities provided by innovative technologies.
Our R&D strategy will provide a future platform from which Lundbeck can discover and develop drugs with clearly documented effects on biologically defined patient groups. It is expected that society’s demand for these new types of drugs will increase.
Our R&D organization
As a medium-sized pharmaceutical company, we share common values in the way we work worldwide and keep a clear focus in our R&D strategy. Research at Lundbeck is based on the efforts of our multi-disciplinary, empowered project teams, our in-house expertise in the brain disease area and our state-of-the-art technologies. We work in new, well-equipped laboratories. In each project team, we integrate our advanced knowledge in R&D disciplines with expertise in clinical practices and therapeutic needs.
Our R&D organization is international and consists of more than 800 dedicated R&D staff. The research organization is located in Copenhagen, Denmark. Development headquarters are also situated in Copenhagen, Denmark with clinical research and regulatory personnel spread worldwide.
Respect for the individual
In Lundbeck, we work together as individuals towards common goals. We seek to constantly develop and improve our scientific and personal skills and qualifications. This allows us to promote career opportunities for the individual, as well as maintain and develop our competencies as an organization. Publication of our scientific results is a natural part of our participation as active members in the international scientific community.
Publications and clinical trials
Lundbeck’s mission is to improve the quality of life of people suffering from psychiatric and neurological disorders. As a pharmaceutical company, Lundbeck considers the sharing of information from company-sponsored clinical trials to be an important part of fulfilling this mission. Lundbeck publishes the results from our research and clinical studies in scientific journals and presents these results at scientific conferences. Lundbeck also discloses clinical trial information and results summaries in public registries and shares clinical data. The Lundbeck policy for scientific publications and responsible clinical trial data sharing covers all scientific publications authored by Lundbeck and clinical trial data sharing for trials sponsored by H. Lundbeck A/S.
For more information on our publications click here.
Details of clinical trials conducted by Lundbeck can be found on ClinicalTrials.gov and the EU Clinical Trials Register.